Skip to main content

Improved glioblastoma treatment through targeted, local drug delivery

Project description

Testing a novel drug delivery platform for glioblastoma

Glioblastoma is the most aggressive brain tumour with an extremely poor prognosis. The aggressiveness and location of the tumour hamper the efficacy of available treatments. The EU-funded TARGLIO project has developed SI053, a unique polymer matrix that contains the first-line chemotherapeutic drug temozolomide. SI053 delivers the drug locally, overcoming the blood–brain barrier and avoiding the toxic side effects associated with systemic administration. The TARGLIO drug delivery platform can be applied immediately after surgery and continues to slowly release the drug. The project is undertaking a clinical trial to validate the safety and efficacy of SI053, supporting its commercialisation and clinical application.

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Coordinator

DOUBLE BOND PHARMACEUTICAL AB
Address
Virdings Alle 32 B Ltr
75450 Uppsala
Sweden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000